Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Advance Auto Parts, Inc. (AAP) vs Nuvalent Inc (NUVL) Price & Performance

Advance Auto Parts, Inc.
Nuvalent Inc

Price performance

Price movement over the last 24 hours

Key statistics

Advance Auto Parts, Inc. vs Nuvalent Inc — how do they compare? Advance Auto Parts, Inc. trades at $54.95 (market cap $3.37B), while Nuvalent Inc trades at $123.83 (market cap $9.80B). The key difference: Nuvalent Inc is far larger — about 2.9× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

AAPNUVL
Market Cap
$3.37B$9.80B
Sector
Consumer CyclicalTechnology
52-Week High
$66.50$123.77
52-Week Low
$38.75$72.16
Enterprise Value
$5.64B$8.51B
Dividend Yield
1.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advance Auto Parts, Inc.

Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.

The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.72, down slightly by 0.01% on the day, with a price-to-book ratio of 8.34. The stock exhibits a bullish technical trend, supported by strong moving averages, though RSI levels indicate overbought conditions. Recent financials show negative profitability, with a net loss of $425.38 million in 2025 and negative operating cash flow, but the company secured $515.34 million in financing. A major development is the pending $10.6 billion acquisition by GSK at $124 per share, announced in June 2026, which has driven significant investor attention and legal scrutiny over fairness.

The outlook for NUVL is heavily influenced by the GSK acquisition, offering a near-term exit at $124 per share. Risks include ongoing shareholder investigations into the deal's fairness and the company's persistent losses. Analyst sentiment is mixed, with 42% recommending buy and 58% hold, reflecting uncertainty around the acquisition's completion and valuation. Investors should monitor regulatory approvals and any competing offers that may emerge, as these will determine final shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Advance Auto Parts, Inc.

Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.

Read more on AAP

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL